Significance of the Genomic Landscape of a De Novo Endocrine-Resistant Metastatic Hormone Receptor–Positive Breast Cancer
Endocrine therapy with or without CDK4/6 inhibitors is the most commonly used frontline treatment option for metastatic hormone receptor–positive breast cancer. Approximately, 25% to 30% of women may have resistance to endocrine therapy, especially in the setting of certain genomic mutations in the...
Main Authors: | Maithreyi Sarma, Yara Abdou, Ajay Dhakal, Shipra Gandhi |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-12-01
|
Series: | Breast Cancer: Basic and Clinical Research |
Online Access: | https://doi.org/10.1177/1178223420976387 |
Similar Items
-
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
by: Anishka D’Souza, et al.
Published: (2018-06-01) -
Metastatic breast cancer: Endocrine therapy landscape reshaped
by: Mohamad Adham Salkeni, et al.
Published: (2017-10-01) -
Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer
by: Li Bian, et al.
Published: (2020-10-01) -
RETRACTION: Challenges of combined everolimus/endocrine therapy in hormone receptor-positive metastatic breast cancer
by: Camillo Porta
Published: (2014-06-01) -
RETRACTED - Challenges of combined everolimus/endocrine therapy in hormone receptor-positive metastatic breast cancer
by: Yousif Abubakr, et al.
Published: (2014-03-01)